Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.
Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.
Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:
- Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
- Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
- Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.
Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.
SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.
For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.
Rhea-AI Summary
SOPHiA GENETICS partners with Karkinos Healthcare to advance cancer research and personalized cancer care in India. The partnership aims to expand access to precision oncology and equip local health institutions with the tools and technology needed to practice data-driven medicine. Karkinos Healthcare will use the SOPHiA DDM™ Platform to advance research and streamline workflow for a variety of blood cancers and solid tumors, with a focus on precision medicine for the underprivileged population of India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.62%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) reports continued revenue growth driven by strong adoption and analysis volume of the SOPHiA DDM™ Platform. The company will present its near-term growth strategy at the 42nd annual J.P. Morgan Healthcare Conference, highlighting a record 315,000+ analyses globally in 2023, with over 1.5 million genomic profiles analyzed worldwide. New customer count for 2023 includes 87 core genomics customers globally, resulting in a current network of 750+ customers using SOPHiA DDM™ globally. The company also announced new U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application, and The Royal Marsden live on the SOPHiA DDM™ Platform to support HRD testing and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) collaborates with Exactis Innovation, a non-profit network of hospital partners across Canada, to fuel cancer research and data-driven decision-making through the SOPHiA DDM™ platform. The collaboration aims to improve cancer survivorship in Canada by leveraging real-world data insights from multimodal datasets. The partnership will also enable Exactis to implement leading cancer testing solutions for its patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) partners with Hôpital Saint-Louis in Paris to implement the SOPHiA DDM™ Platform for research on Myeloid Disorders, aiming to provide data-driven care to patients with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (NASDAQ: SOPH) CEO Jurgi Camblong, PhD., to present at J.P. Morgan 2024 Healthcare Conference on January 11, 2024, in San Francisco.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) expands its suite of solutions under SOPHiA DDM™ for Liquid Biopsy, offering MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions to advance oncology research and tumor mutation profiling. Liquid biopsy testing provides an alternative to solid tumor testing by isolating cell-free DNA from blood plasma, allowing for faster, less invasive clinical decisions and simplified monitoring. The company's proprietary unique molecular identifier technology (CUMIN™) promises exceptional performance and reliable results in analyzing cell-free DNA samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announces expanded research partnership with CHU de Nîmes, a regional and university hospital in France. CHU de Nîmes will utilize SOPHiA DDM™ Platform for pharmacogenomics research, aiming to personalize medication response based on genetic profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (SOPH) expands its relationship with Città della Salute e della Scienza di Torino, the largest health center in Italy, to further utilize the SOPHiA DDM™ Platform on Microsoft Azure for research on homologous recombination repair (HRR) biomarkers. The cloud-native software company aims to support the hospital's research in various cancer types and rare diseases, revolutionizing data-driven medicine capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
-
News
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), is now live on the SOPHiA DDM™ Platform to advance its research into rare disorders, particularly male fertility. IHG PAS will use SOPHiA DDM™ Whole Exome Solution (WES) for next-generation sequencing (NGS) to accelerate research of inherited diseases, including infertility. The platform provides overnight analysis of WES and a rich knowledge base to help identify variants of interest associated with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
FAQ
What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
The current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH) is $3.26 as of December 20, 2024.
What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
The market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH) is approximately 206.0M.
What does SOPHiA GENETICS do?
SOPHiA GENETICS is a healthcare technology company that leverages AI to analyze complex genomic and multimodal data, providing insights for clinical diagnostics and life sciences research.
What is the SOPHiA DDM™ Platform?
The SOPHiA DDM™ Platform is a cloud-based SaaS solution that analyzes next-generation sequencing (NGS) data and integrates various diagnostic modalities to deliver actionable insights for healthcare providers.
Where is SOPHiA GENETICS based?
SOPHiA GENETICS is headquartered in Switzerland, with a physical presence in France, the United States, and Brazil.
Who are some of SOPHiA GENETICS' partners?
Recent partners include Unilabs in Europe, Syndicate Bio in Nigeria, Klinikum Klagenfurt in Austria, and Instituto Mário Penna in Brazil.
What is SOPHiA UNITY?
SOPHiA UNITY is a data-driven consortium designed to accelerate cancer research globally by bringing together healthcare institutions to share and analyze diverse, high-quality data.
How does SOPHiA GENETICS support precision medicine?
Through its SOPHiA DDM™ Platform, SOPHiA GENETICS enables healthcare providers to perform fast, accurate genetic analyses, facilitating data-driven treatment decisions and advancing precision medicine.
What recent advancements have SOPHiA GENETICS made?
Recent advancements include the integration of their platform by Unilabs for HRD-testing in tumors, the launch of WGS solutions in collaboration with Microsoft and NVIDIA, and the formation of SOPHiA UNITY for cancer research.
What is the company's mission?
SOPHiA GENETICS' mission is to expand access to data-driven medicine globally, using AI to provide world-class care to patients with cancer and rare disorders.
How does SOPHiA GENETICS ensure data privacy and quality?
The company employs advanced bioinformatics and machine learning technologies to ensure high-quality analysis and secure banking of patient DNA sequence data, maintaining stringent privacy standards.
How can I learn more about SOPHiA GENETICS?
For more information, visit their website at SOPHiAGENETICS.com or connect with them on social media platforms like LinkedIn, X, Facebook, and Instagram.
SOPHiA GENETICS SA Ordinary Shares
Nasdaq:SOPH
SOPH Rankings
SOPH Stock Data
205.96M
62.57M
5.82%
53.4%
0.09%
Health Information Services
Healthcare
United States of America
Rolle